Wharton's Jelly-derived Mesenchymal Stem Cells in Osteoarthritis

Inclusion Criteria: * presence of osteoarthritis of the knee, hip or glenohumeral joint, * confirmation cartilage injury, articular cartilage part or full-thickness injury by MR (Magnetic Resonance), * joint pain of VAS (visual analog scale score) is 1 or higher while resting, 2 and higher during any physical activity, * loss of joint function based on scale specific for certain joints; for hip: HHS scale (Harris Hip Score), HOOS scale (Hip disability and Osteoarthritis Outcome Score), The Western Ontario and McMaster Universities Arthritis Index (WOMAC); for knee: modified HHS score (Harris Hip Score), The Western Ontario and McMaster Universities Arthritis Index (WOMAC), The International Knee Documentation Committee (IKDC Questionnaire) and KOOS scale (Osteoarthritis Outcome Score); glenohumeral joint: Disability of Arm, Shoulder and Hand \[DASH\], CONSTANT score, * clinical indication for surgical intervention, * no effect of pharmacotherapy according to The World Health Organization (WHO) analgesic ladder lasting at least 6 months, * no effect of physical rehabilitation lasting at least 6 months, * willing to participate understand and sign the consent form of this study. Exclusion Criteria: * active inflammatory disease or infection, * skin disease/infection around joint, * severe heart failure, * anemia, * active/history of human immunodeficiency viruses (HIV), the hepatitis B virus (HBV) or the hepatitis C virus (HCV) infection, * pregnant or breast-feeding women, …